ResearchSafe

Nature asks if living to 150 is realistic, and I'm not sold

Posted by jared467 in Research & News - 1 points, 4 comments.

https://www.timeline.com/blog/2025-breakthroughs-in-longevity-research

Nature has a piece asking whether humans could actually hit 150 years old soon, and which researchers think we are close. I clicked it expecting new data, but it reads more like a roundup of opinions from people in the field, with the usual suspects like rapamycin, metformin, and cellular reprogramming mentioned.

What bugs me is the framing. Whenever I see "we are on the cusp" in a headline, my guard goes up. Anecdotally, the people I follow who actually run these protocols are not talking about living to 150. They are talking about better healthspans, fewer sick days, maybe a couple extra years at the end. That feels more honest to me than the "cusp of a breakthrough" language.

The article does mention the obvious counterpoints, like biological limits and quality of life concerns, but it still leans optimistic. Has anyone here read it and felt differently?

Comments

  • aaron_n: Tbh I think you're right to call out the framing, the "cusp" stuff is mostly clickbait and Nature knows it. The gap between what researchers actually show in the data and what gets paraphrased into headlines is wild to me, like mtor stuff in mice doesn't translate 1:1 to humans, and most of the longevity crowd I follow are basically just trying to feel better at 70, not hit 150. Curious what you mean by "usual suspects" though, are you including the senolytics folks in that or just the rapamyc
  • jared467: Yeah, I meant rapamycin, metformin, and cellular reprogramming mostly. Senolytics like dasatinib plus quercetin are a different category, you're right, more like clearing out damaged cells rather than the mtor/AMPK pathway stuff. I lumped them together too quickly, my bad 😅
  • aspiringhana: I meant the mTOR / AMPK / reprogramming cluster, so rapamycin, metformin, Yamanaka factors mostly. I keep senolytics in a separate box in my head because the mechanism is different, you are clearing senescent cells rather than tweaking signaling pathways, even if D+Q gets lumped in casually online. Anecdotally the senolytic papers seem more variable to me, some look promising and some I can't reproduce the effect when I dig into the methods.
  • jared467: Yeah that makes sense, and I think I was lumping them together because most articles do the same. The D+Q stuff especially gets thrown in with the mTOR crowd even though like you said, it is a different mechanism. I have not looked at senolytics papers closely yet, only rapamycin and metformin so far. When you say variable, is that mostly small sample sizes or is it more about the methods being hard to replicate? I am trying to figure out where to spend my reading time 😅

Community discussion - research and educational context only. Not medical advice.